Novavax set up the joint venture, CPL Biologicals, as part of its strategy of partnering with pharma firms to expand its vaccine production capabilities to other counties.
The Indian plant is now operational and is expected to have a bulk capacity of 60m doses of virus-like particle (VLP) influenza vaccine a year. Sterile filling capabilities are also housed at the site.
Rahul Singhvi, president and CEO of Novavax, said the facility has “an efficient, reliable and flexible vaccine production process" which will supply India and other countries.
CPLB will also develop, manufacture and sell biosimilars and diagnostic kits.